"Cumberland’s Vibativ injection gains China’s NMPA approval" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on th ...
China's National Medical Products Administration (NMPA) has approved Keymed Biosciences’ supplemental new drug application ...
School of Pharmacy, Fudan University, Pudong, Shanghai, China. In 2024, the China National Medical Products Administration (NMPA) approved a total of 228 new drug applications (NDAs), including ...
China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...
Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis
CHENGDU, China, Feb. 7, 2025 /PRNewswire/ -- KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the ...
Up to date, HANSIZHUANG has been approved by the National Medicinal Products Administration (NMPA) for the treatment of squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell ...
Pharmaceuticals announced the NMPA, National Medical Products Administration, approval of Cumberland’s Vibativ injection in ...
China's National Medical Products Administration (NMPA) has approved Keymed Biosciences’ supplemental new drug application (NDA) for Stapokibart to treat seasonal allergic rhinitis. The approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback